The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.
The FDA approved mavacamten (Camzyos), a cardiac myosin inhibitor, for the treatment of adult patients with New York Heart Association class II to III obstructive hypertrophic cardiomyopathy (HCM) in 2022. Milind Desai, MD, MBA, Cleveland Clinic, reported on the drug’s safety profile and efficacy at this year’s American Heart Association (AHA) Scientific Sessions. At present, he was able to speak to the real-world, 22-month data on mavacamten and the role of a risk evaluation and mitigation strategy (REMS) program for monitoring patients.
Desai discussed in more detail the process of implementing the REMS program, which their findings suggest was a valuable tool in assessing the benefits of mavacamten and its ability to improve patients’ functional lung capacity and other associated disease symptoms.
This transcript has been lightly edited for clarity and length.
Transcript
What have been the main challenges or successes in implementing the REMS monitoring for patients on mavacamten, and how has it influenced the overall safety profile in real-world use?
So the REMS program, or the risk evaluation mitigation strategy program, is something that the FDA mandates in situations where they want to ensure safety of a new drug in a postapproval phase when it is marketed to a broader audience, a broader group of patients. They want to emphasize that there is convincing follow-up in terms of beyond what a package insert can offer, so clearly, not every drug gets the REMS labeling, and not every provider is well-versed with the REMS program.
So the biggest initial challenge was [providers asking,] “What is it? How do we incorporate that in our practice? How do we operationalize this? How do we explain it to the patients?” in addition to all the challenges that come with launching or rather trialing a new drug. I think those were the initial challenges. Most places, most larger HCM centers, have learned to develop the robust processes that work in terms of implementing the REMS program, including working with the specialty pharmacies, including making the patients understand, and including making themselves—the providers, as well as their teams—understand. So, I think it was a major, steep learning curve. And pretty much the ones that use mavacamten frequently have gotten used to it, and, to use a golfing term now, it's pretty much par for the course in a lot of places.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
No Major Shifts in OBGYN Practice Locations Found Post Dobbs Decision
April 21st 2025Despite widespread concern following the Dobbs v Jackson Women’s Health Organization decision, researchers found no significant changes nationwide in obstetrician and gynecologist (OBGYN) practice locations.
Read More